Ontology highlight
ABSTRACT:
SUBMITTER: Ravandi F
PROVIDER: S-EPMC4081177 | biostudies-literature | 2010 Sep
REPOSITORIES: biostudies-literature
Ravandi Farhad F O'Brien Susan S Thomas Deborah D Faderl Stefan S Jones Dan D Garris Rebecca R Dara Samuel S Jorgensen Jeffrey J Kebriaei Partow P Champlin Richard R Borthakur Gautam G Burger Jan J Ferrajoli Alessandra A Garcia-Manero Guillermo G Wierda William W Cortes Jorge J Kantarjian Hagop H
Blood 20100513 12
The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph(+) ALL. Newly diagnosed patients received dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of a ...[more]